BIIB · Healthcare
BIOGEN INC
7
Tracked Holders
Limited info. BIOGEN INC is not currently in our model portfolio, but 7 tracked investors hold it. We're showing what we know from their latest 13F filings.
Market cap
$30.6B
Industry
Drug Manufacturers - General
Exchange
NasdaqGS
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the…
7
Investors
1
New positions
1
Increasing
4
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
1.1%
Position change
NEW
1.1% of Glenview Capital Mgmt's portfolio
Trust weight: 1.1×
% of portfolio
0.2%
Position change
+2%
0.2% of Gotham Asset Mgmt's portfolio
Trust weight: 1.1×
% of portfolio
0.8%
Position change
−27%
0.8% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
—
0.1% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−14%
0.1% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−89%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−89%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to BIOGEN INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell BIOGEN INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime